Welcome to our dedicated page for Aptevo Therapeutics news (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics stock.
Aptevo Therapeutics Inc. (NASDAQ: APVO) is a clinical-stage biotechnology company advancing novel bispecific antibody therapies for cancer treatment. This news hub provides investors and industry professionals with timely updates on APVO's clinical developments, platform innovations, and strategic milestones.
Our curated collection features official press releases and verified news about the company's ADAPTIR platform progress, clinical trial results for candidates like mipletamig in AML, and regulatory updates. Users will find updates on financial filings, research collaborations, and therapeutic pipeline expansions across hematologic malignancies and solid tumors.
This resource serves as a centralized reference for tracking APVO's progress in developing targeted immunotherapies designed to improve treatment safety and efficacy. Content is organized chronologically with clear sourcing to ensure reliable tracking of the company's scientific advancements and corporate developments.
Bookmark this page for streamlined access to APVO's latest announcements, including trial initiations, data presentations at medical conferences, and partnership disclosures. Check regularly for updates on how the company's modular protein engineering approaches aim to address unmet needs in oncology care.
Aptevo Therapeutics (NASDAQ:APVO) has announced a 1-for-20 reverse stock split effective May 23, 2025, at 5:01 p.m. Eastern Time. Trading on the adjusted basis will begin on May 27, 2025. The reverse split will reduce outstanding shares from approximately 13.5 million to 0.7 million.
The measure, approved by stockholders on May 14, 2025, and finalized by the Board on May 21, 2025, is part of the company's strategy to maintain Nasdaq Capital Market listing compliance. The split will affect all outstanding shares, options, restricted stock units, and warrants. No fractional shares will be issued, with cash payments provided instead. The trading symbol "APVO" and the stock's par value of $0.001 will remain unchanged.
- 5 out of 6 patients in RAINIER trial achieved remission within 30 days - No cytokine release syndrome (CRS) observed in current trial - One patient achieved complete remission with MRD-negative status - Cohort 2 enrollment completed, Cohort 3 now enrolling
The drug has been tested in nearly 100 patients across three clinical studies, showing promising results in both combination and monotherapy settings. In monotherapy trials, 36% of evaluable patients who failed prior treatments showed significant leukemic blast reduction. The company plans multiple data readouts in 2025.
Aptevo Therapeutics (NASDAQ: APVO) provided an update on APVO711, their preclinical-stage bispecific therapeutic candidate. APVO711 is designed with a dual mechanism that combines PD-L1 checkpoint inhibition with CD40 immune activation, developed using their proprietary ADAPTIR® platform technology.
The company's lead candidate mipletamig continues to show strong efficacy and safety results in AML trials. APVO711 demonstrates promising preclinical results with potential applications across various solid tumors, particularly those resistant to conventional checkpoint therapies. The therapeutic aims to achieve deeper and more sustained responses through its innovative dual-mechanism approach.
Applied Materials (AMAT) has announced it will release its fiscal second quarter 2025 financial results on May 15, 2025.
Aptevo Therapeutics (Nasdaq: APVO), a clinical-stage biotechnology company, has completed its previously announced registered direct offering, raising $2.0 million through the sale of 2,324,000 shares of common stock at $0.862 per share.
The offering was conducted at-the-market under Nasdaq rules, with Roth Capital Partners serving as the exclusive placement agent. The company plans to utilize the net proceeds for continued clinical development of its product candidates, working capital, and general corporate purposes.
The offering was made through a shelf registration statement on Form S-3 (File No. 333-284969) previously filed with the SEC. Aptevo specializes in developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies.